//./ActionParams/@language -> $page_language ->

Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,913.455.3
Stock Analysis, IPO, Mutual Funds, Bonds & More

Aurobindo Pharma Ltd.

ET 500

Rank 2018
91
ENGNew
  • ENG - English
  • HIN - हिन्दी
  • GUJ - ગુજરાતી
  • MAR - मराठी
  • BEN - বাংলা 
  • KAN - ಕನ್ನಡ 
  • ORI - ଓଡିଆ
  • TEL - తెలుగు
  • TAM - தமிழ்
  • NSE
    16:00 | 11-11-2019
  • BSE
    15:44 | 11-11-2019
437.70

Today's Change

-2.25 (-0.51%)

Volume
AVERAGE VOLUME
5-Day
10-Day
30-Day

4,784,575

Open

437.00

Prev. Close

439.95

Day's Trend

  • Bid
  • Mkt Cap (₹ Cr.)
  • P/E (x)
  • P/B (x)
  • Div_ Yield (%)
  • BETA
    BETA
    1 Month
    3-Months
    6-Months
    1 Year
    3-Years
  • Offer
  • Face Value (₹)1.00
  • EPS-TTM (Rs.)43.43
  • BV/share (₹)237.11
  • 52Wk L/H431.30/ 838.00
  • Avg. Daily Volatility %
    Avg. Daily Volatility %
    1 Month
    3-Months
    6-Months
    1 Year
    3-Years
InsightsEvents| Recos| Updates| News| Speed

Aurobindo Pharma Ltd Stock Price F & O Quotes

Buy Aurobindo Pharma, target Rs 640: Kunal Bothra| Recos
Buy
Buy Aurobindo Pharma, target Rs 625: CK Narayan| Recos
Buy
Buy Aurobindo Pharma, target Rs 618: Jay Thakkar| Recos
Buy
Buy Aurobindo Pharma, target Rs 618: Dr CK Narayan| Recos
Buy
Buy Aurobindo Pharma, target Rs 650: Kunal Bothra| Recos
Buy
Sell Aurobindo Pharma, target Rs 540: Manas Jaiswal| Recos
Sell
Sell Aurobindo Pharma, target Rs 584: Dr CK Narayan| Recos
Sell
Buy Aurobindo Pharma, target Rs 705: ICICI Direct| Recos
Buy
Buy Aurobindo Pharma, target Rs 865: Kunal Bothra| Recos
Buy
Buy Aurobindo Pharma, target Rs 850: Dr CK Narayan| Recos
Buy
Buy Aurobindo Pharma, target Rs 820: Kunal Bothra| Recos
Buy
Buy Aurobindo Pharma, target Rs 793: JM Financial| Recos
Buy
Buy Aurobindo Pharma, target Rs 805: Kunal Bothra| Recos
Buy
Aurobindo Pharma Ltd.Clarification On News Article AurobindoS Buyout Of Sandoz Assets Delayed On FTC Query Appeared In ET On November 7, 2019...| Announcement
Aurobindo Pharma Ltd.Analyst / Investor Call| Announcement
Aurobindo Pharma Ltd.Clarification On News Article Aurobindo Pharma Under USFDA Scrutiny - Reg.,| Announcement
Aurobindo Pharma Ltd.Clarification sought from Aurobindo Pharma Ltd| Announcement
Aurobindo Pharma under USFDA scrutiny| News
Aurobindo Pharma Ltd.Board to consider Q2 results & Interim Dividend on Nov 12, 2019| Announcement
Aurobindo Pharma Ltd.Board Meeting Intimation for Board Meeting To Consider The Unaudited Financial Results Of The Company For The Second Qua...| Announcement
Aurobindo Pharma Ltd.Announcement under Regulation 30 (LODR)-Newspaper Publication| Announcement
Aurobindo Pharma Ltd.Announcement under Regulation 30 (LODR)-Meeting Updates| Announcement
Aurobindo Pharma Ltd.Announcement under Regulation 30 (LODR)-Newspaper Publication| Announcement
Aurobindo Pharma Ltd.Announcement under Regulation 30 (LODR)-Newspaper Publication| Announcement
Aurobindo Pharma Ltd.Notice Of The Meeting Of The Equity Shareholders Of Aurobindo Pharma Limited To Be Convened Pursuant To The Directions O...| Announcement
Aurobindo Pharma Ltd.Announcement under Regulation 30 (LODR)-Press Release / Media Release| Announcement
Aurobindo Pharma Ltd.Shareholding for the Period Ended September 30, 2019| Announcement
Aurobindo Pharma Ltd.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018| Announcement
Aurobindo Pharma Ltd.Statement Of Investor Complaints For The Quarter Ended September 2019| Announcement
Aurobindo Pharma Ltd.Share Transfer Agent - Compliance Certificate For The Half Year Ended 30.09.2019| Announcement
Aurobindo Pharma Ltd.Compliance Certificate Under Regulation 40(9) For The Half Year Ended 30.09.2019| Announcement
Aurobindo Pharma Ltd.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011| Announcement
Aurobindo Pharma Ltd.Clarification On Reporting Under Regulation 30 Of SEBI (LODR) Regulations, 2015. Ref : E-Mail Dated October 11, 2019 Re...| Announcement
Aurobindo Pharma Ltd.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.| Announcement
Aurobindo Pharma Ltd. share price down by -0.51% from its previous close of Rs 439.95. Aurobindo Pharma Ltd. stock last traded price is 437.70
Aurobindo Pharma Ltd. Share Price
Value
Today/Current/Last
437.70
Previous Day
439.95
What's your view on Aurobindo Pharma for the week?
Bearish
Bullish
View community Outlook >>

Be the first one to post on Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.
Quarterly Results

Figures in Rs. Cr
Jun 2019 
% Chg (Quarterly)
% Chg (Yearly)
Peer Range
Trend
Last 12 Quarters Trend
Sales
5,356.84
2.98
28.11
0.00
8374.36
Other Operating Income
87.76
-2.73
27.73
0.00
115.06
Operating Profit
1,146.40
8.41
61.22
-95.02
2805.84
Other Income
15.78
-51.10
-63.91
0.00
430.10
EBITDA
1,162.18
6.65
53.97
-95.02
2805.84
Interest
49.89
-0.38
68.89
0.00
122.00
Depreciation
240.86
29.06
55.87
0.00
457.13
Tax
227.76
-1.45
97.13
-40.98
227.98
Net Profit
635.68
8.59
39.51
-94.19
1387.48
EPS (₹)
10.85
8.61
39.46
-9.29
40.74

Aurobindo Pharma Ltd Share Price

Vs Peers
Companies
LTP
Intraday
1W %
1M %
1 QTR %
1 YR %
3 YR %
5 Yr %
Trend -
D|M|Y
437.70
-0.51
-7.64
-0.28
-26.91
-45.01
-45.01
-45.01
230.45
-0.84
-3.82
0.15
0.04
-35.30
-35.30
-35.30
263.50
-0.57
2.83
6.42
15.12
-15.84
-15.84
-15.84
454.85
-1.65
-2.78
3.06
-6.12
-14.48
-14.48
-14.48
735.75
2.37
-2.54
4.86
-3.02
-14.44
-14.44
-14.44
1972.00
-3.06
-3.75
1.27
11.89
0.49
0.49
0.49
1803.45
-0.62
0.66
9.68
7.70
9.65
9.65
9.65
1710.55
0.62
1.37
1.22
2.74
13.15
13.15
13.15
330.65
0.09
0.12
6.68
5.20
13.53
13.53
13.53
2815.75
-0.23
0.00
6.20
9.42
16.57
16.57
16.57
815.90
0.46
-3.44
6.03
-7.65
17.98
17.98
17.98
Top Loser for the period amongst the peers
Top Gainer for the period amongst the peers

Aurobindo Pharma Ltd Risk Return Comparison

with peersNew

Aurobindo Pharma Ltd
Financial Comparison

with peers
Management Efficiency
Aurobindo Pharma Ltd 
peer Average
Peer Range
Trend
Return on Equity (%)
17.02
8.87
-99.01
47.57
Return on Assets (%)
9.06
5.79
-27.48
26.25
Return on capital Employed (%)
10.35
6.57
-130.86
23.01
Fixed Assets Turnover (x)
1.06
0.97
0.00
2.79
Profitability and Growth
Gross Profit Margin (%)
16.78
-8.77
-980.00
34.42
Operating Profit Margin(%)
20.20
0.38
-896.19
37.94
Net Profit margin (%)
12.08
2.06
-461.80
94.28
Financial Strength
Liquidity
Quick Ratio (x)
1.47
1.65
0.08
9.50
Current Ratio (x)
2.75
2.40
0.21
9.50
Cash ratio (x)
0.34
0.22
-0.52
1.40
Solvency
Debt Equity Ratio (x)
0.01
0.27
0.00
1.77
Coverage Ratios
Cash flows to long term debt (x)
2.17
3.76
0.00
45.52
Better performer than its peers on this ratioAverage performer than its peers on this ratioUnderperformer than its peers on this ratio

Aurobindo Pharma Ltd Share Holding as on 30-09-2019

CategoryNo. of sharesPercentage
Promoters285,925,93448.80
ForeignInstitutions128,642,42621.95
NBanksMutualFunds74,172,80612.66
GeneralPublic50,169,2168.56
Others27,073,6484.62
ForeignPromoter18,000,0003.07
FinancialInstitutions1,954,5790.33

MF Ownership Of Aurobindo Pharma Ltd. Shares

Fund Name
Category
No. of shares
% Change in Shares (MOM basis)
% of AUM
Amount Invested (in ₹ Cr)
HDFC Balanced Advantage Direct-G
Portfolio as on 31-10-2019
Hybrid: Dynamic Asset Allocation
8570828
0.00%
0.91%
402.70
HDFC Equity Direct-G
Portfolio as on 31-10-2019
Equity: Multi Cap
8490444
33.11%
1.7%
398.92
HDFC Hybrid Equity Direct-G
Portfolio as on 31-10-2019
Hybrid: Aggressive Hybrid
7361000
0.00%
1.64%
345.86
HDFC Mid-Cap Opportunities Direct-G
Portfolio as on 31-10-2019
Equity: Mid Cap
4127400
0.00%
0.86%
193.93

Liquid, Ultra Short Term funds and FMPs are not taken into account.

More Schemes

About Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 25640.67 Crore) operating in Pharmaceuticals sector.

Aurobindo Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 11922.63 Crore to Sales Value (97.26 % of Total Sales), Export Incentives which contributed Rs 303.72 Crore to Sales Value (2.47 % of Total Sales), Sale of services which contributed Rs 16.07 Crore to Sales Value (0.13 % of Total Sales) and Scrap which contributed Rs 15.47 Crore to Sales Value (0.12 % of Total Sales)for the year ending 31-Mar-2019.

For the quarter ended 30-06-2019, the company has reported a Consolidated sales of Rs 5356.84 Crore, up 2.98 % from last quarter Sales of Rs 5201.98 Crore and up 28.11 % from last year same quarter Sales of Rs 4181.56 Crore Company has reported net profit after tax of Rs 630.97 Crore in latest quarter.

The company’s top management includes Dr.M Sivakumaran, Dr.(Mrs.)Avnit Bimal Singh, Mr.K Nithyananda Reddy, Mr.K Ragunathan, Mr.M Madan Mohan Reddy, Mr.M Sitarama Murthy, Mr.N Govindarajan, Mr.P Sarath Chandra Reddy, Mr.P V Ramprasad Reddy, Mrs.Savita Mahajan. Company has BSR & Associates LLP as its auditoRs As on 30-09-2019, the company has a total of 585,938,609 shares outstanding.

Close X
WatchlistPortfolio

Current Price>: 2389.88

Set Alert

Loading
Please wait...

Date Sources:Live BSE and NSE Quotes Service: TickerPlant | Corporate Data, F&O Data & Historical price volume data: Dion Global Solutions Ltd.
BSE Quotes and Sensex are real-time and licensed from the Bombay Stock Exchange. NSE Quotes and Nifty are also real time and licenced from National Stock Exchange. All times stamps are reflecting IST (Indian Standard Time).
By using this site, you agree to the Terms of Service and Privacy Policy.

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

Loadingdata
More on:
Prices| Financials | Company Info | Reports | News | Competitors